IRIS  Catalogo Istituzionale della Ricerca dell'Università degli Studi del Molise

MARFELLA, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.265
EU - Europa 2.076
AS - Asia 849
SA - Sud America 263
AF - Africa 130
OC - Oceania 1
Totale 5.584
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.189
RU - Federazione Russa 1.526
SG - Singapore 342
BR - Brasile 189
CN - Cina 177
DE - Germania 131
FR - Francia 114
VN - Vietnam 100
CI - Costa d'Avorio 96
IT - Italia 82
HK - Hong Kong 71
GB - Regno Unito 54
CA - Canada 39
IN - India 28
MX - Messico 28
PL - Polonia 26
IE - Irlanda 25
BD - Bangladesh 23
AR - Argentina 22
FI - Finlandia 20
ES - Italia 19
IQ - Iraq 17
ZA - Sudafrica 17
ID - Indonesia 16
NL - Olanda 16
AT - Austria 13
JP - Giappone 13
UA - Ucraina 12
EC - Ecuador 11
CO - Colombia 10
CZ - Repubblica Ceca 10
LT - Lituania 9
CL - Cile 8
VE - Venezuela 7
PK - Pakistan 6
SE - Svezia 6
TR - Turchia 6
AE - Emirati Arabi Uniti 5
BO - Bolivia 5
JO - Giordania 5
MA - Marocco 5
PH - Filippine 5
SA - Arabia Saudita 5
UY - Uruguay 5
MY - Malesia 4
PE - Perù 4
RO - Romania 4
TH - Thailandia 4
UZ - Uzbekistan 4
DZ - Algeria 3
HN - Honduras 3
PT - Portogallo 3
TW - Taiwan 3
BE - Belgio 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
EG - Egitto 2
IL - Israele 2
PY - Paraguay 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BZ - Belize 1
CG - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
ET - Etiopia 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
LY - Libia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
Totale 5.584
Salva come PNG Salva come JPEG
Città #
Dallas 1.006
Moscow 520
San Jose 324
Ashburn 189
Singapore 186
Abidjan 96
Frankfurt am Main 91
Beijing 80
Hong Kong 70
The Dalles 70
Lauterbourg 55
Los Angeles 45
Ho Chi Minh City 43
New York 39
Boardman 27
Dublin 25
Warsaw 24
Orem 22
Denver 20
Hanoi 20
Santa Clara 20
São Paulo 20
Chennai 18
Montreal 16
Munich 16
Brooklyn 14
London 14
Amsterdam 13
Poplar 13
Tokyo 13
Campobasso 10
Chicago 10
Helsinki 10
Jacksonville 10
Manchester 10
Nuremberg 10
Council Bluffs 9
Mexico City 9
Phoenix 9
Atlanta 8
Boston 8
Brno 8
Columbus 8
Houston 8
Johannesburg 8
Naples 8
Querétaro 8
San Francisco 8
Terzigno 8
Chandler 7
Falkenstein 7
Hillsboro 7
Roubaix 7
Baghdad 6
Curitiba 6
Córdoba 6
Mumbai 6
Rio de Janeiro 6
Toronto 6
Acerra 5
Ankara 5
Bexley 5
Lappeenranta 5
Montevideo 5
Santiago 5
Stockholm 5
Turku 5
Vienna 5
Amman 4
Assago 4
Bangkok 4
Charlotte 4
Da Nang 4
Erbil 4
Guarulhos 4
Jakarta 4
Limburg an der Lahn 4
Ottawa 4
Rome 4
Tashkent 4
Vancouver 4
Baie-D'Urfé 3
Brasília 3
Caracas 3
Casablanca 3
Guayaquil 3
Haiphong 3
Lahore 3
Lima 3
Medellín 3
Mosul 3
Porto Alegre 3
Providence 3
Quito 3
Secaucus 3
Shenzhen 3
Vilnius 3
Volta Redonda 3
Wilmington 3
Bari 2
Totale 3.493
Salva come PNG Salva come JPEG
Nome #
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study 614
ELectrophysiological mechanisms underlying the Inhibitory CArdiac syncope without asystolic significant pause: Therapeutic and prognostic implications. The ELICA randomized trial 137
Advances in the Insulin–Heart Axis: Current Therapies and Future Directions 136
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 134
Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study 132
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors 125
Advances in Nanomedicine for Precision Insulin Delivery 121
Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions 119
Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes 117
Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments 117
Impact of Acute Kidney Injury on the COVID-19 In-Hospital Mortality in Octogenarian Patients: Insights from the COVOCA Study 115
Cardiac Hypertrophy: from Pathophysiological Mechanisms to Heart Failure Development 112
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease 112
The impact of new onset diabetes on cardiovascular risks in orthotopic liver transplant recipients: findings from the COLT study 111
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study 109
Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes 107
Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications 105
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options 103
Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications 102
Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA Study 99
Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations 96
Effects of metformin in heart failure: From pathophysiological rationale to clinical evidence 95
Application and internal validation of lung ultrasound score in COVID-19 setting: The ECOVITA observational study 95
Predictive Value of Fatty Liver Index for Long-Term Cardiovascular Events in Patients Receiving Liver Transplantation: The COLT Study 89
Insulin–Heart Axis: Bridging Physiology to Insulin Resistance 89
CURRENT HEPATOCELLULAR CARCINOMA SYSTEMIC PHARMACOLOGICAL TREATMENT OPTIONS 88
Cardiovascular benefits from gliflozins: Effects on endothelial function 83
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care 81
The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease 80
Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque: role of ubiquitin-proteasome activity 77
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives 74
Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study 72
SGLT2 breast expression could affect the cardiovascular performance in pre-menopausal women with fatty vs. non fatty breast via over-inflammation and sirtuins' down regulation 71
Late Hepatocellular Carcinoma Occurrence in Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Therapy: A Matter of Follow-Up or Something Else? 69
MicroRNAs modulation and clinical outcomes at 1 year of follow-up in obese patients with pre-diabetes treated with metformin vs. placebo 68
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives 67
Exosomal miR-145 and miR-885 Regulate Thrombosis in COVID-19 66
Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma 63
HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis 62
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial 62
Inflammatory Cytokines and SIRT1 Levels in Subcutaneous Abdominal Fat: Relationship With Cardiac Performance in Overweight Pre-diabetics Patients 62
Role of subcutaneous abdominal fat on cardiac function and proinflammatory cytokines in premenopausal obese women 60
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 59
Role of tight glycemic control during acute coronary syndrome on CV outcome in type 2 diabetes 58
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 58
Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? 58
Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study 58
Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options 57
Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study 57
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up 57
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies 55
Metformin: An old drug against old age and associated morbidities 54
Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review 54
Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination 54
Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy 51
Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes 50
Mortality and risk factors of vaccinated and unvaccinated COVID-19 frail patients treated with anti-SARS-CoV-2 monoclonal antibodies. A real-world study 48
Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study 48
Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia 48
Long-Term Prognosis among COVID-19 Patients: The Predictive Role Played by Hyperinflammation and Arrhythmic Disorders in Fatal Outcome 46
Metformin Lactic Acidosis: should we still be afraid? 44
Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers 42
GLP-1 Receptor Agonists Are Associated with Reduced Ascending Aorta Dilatation in Patients with Type 2 Diabetes: A Prospective Study 36
Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm 12
Vericiguat for endothelial dysfunction and CRT response in non-responders: the VERCET prospective observational study 12
Impact of achieving glycated hemoglobin targets on cardiovascular events/mortality: Post-hoc analysis of the nephropathy in diabetes type 2 trial 12
Totale 5.624
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.077
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.077
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 2 0
2021/202210 0 2 0 0 0 0 2 1 1 2 0 2
2022/202347 5 1 0 3 2 2 0 3 25 1 5 0
2023/202493 3 2 2 2 4 15 3 7 1 5 5 44
2024/2025862 130 48 95 11 139 13 22 49 88 23 107 137
2025/20264.585 157 396 816 329 961 887 412 137 212 278 0 0
Totale 5.624